S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
Log in
NASDAQ:AMGN

Amgen Stock Forecast, Price & News

$229.99
-2.47 (-1.06 %)
(As of 02/24/2021 12:00 AM ET)
Add
Compare
Today's Range
$227.71
Now: $229.99
$230.79
50-Day Range
$231.47
MA: $240.57
$258.60
52-Week Range
$177.05
Now: $229.99
$276.69
Volume2.62 million shs
Average Volume2.54 million shs
Market Capitalization$132.83 billion
P/E Ratio18.55
Dividend Yield3.03%
Beta0.76
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Sensipar/Mimpara to treat secondary hyperparathyroidism; and EPOGEN to treat anemia caused by chronic kidney disease. It also markets other products in various markets, including Nplate, Vectibix, Repatha, Parsabiv, BLINCYTO, Aimovig, NEUPOGEN, Otezla, AMGEVITA, KANJINTI, EVENITY, IMLYGIC, MVASI, and Corlanor. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; QIAGEN N.V.; Adaptive Biotechnologies; and Eli Lilly and Company, as well as has a strategic agreement with McKesson Corporation to help improve cancer care in community oncology settings. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Amgen logo

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:AMGN
CUSIP03116210
Phone805-447-1000
Employees23,400
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$23.36 billion
Cash Flow$17.72 per share
Book Value$16.28 per share

Profitability

Net Income$7.84 billion

Miscellaneous

Market Cap$132.83 billion
Next Earnings Date4/29/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

2.46 out of 5 stars

Medical Sector

12th out of 1,958 stocks

Biological Products, Except Diagnostic Industry

2nd out of 177 stocks

Analyst Opinion: 3.3Community Rank: 3.0Dividend Strength: 2.5Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
$229.99
-2.47 (-1.06 %)
(As of 02/24/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AMGN News and Ratings via Email

Sign-up to receive the latest news and ratings for AMGN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Amgen (NASDAQ:AMGN) Frequently Asked Questions

Is Amgen a buy right now?

25 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last year. There are currently 11 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Amgen stock.
View analyst ratings for Amgen
or view top-rated stocks.

What stocks does MarketBeat like better than Amgen?

Wall Street analysts have given Amgen a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Amgen wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Amgen's next earnings date?

Amgen is scheduled to release its next quarterly earnings announcement on Thursday, April 29th 2021.
View our earnings forecast for Amgen
.

How were Amgen's earnings last quarter?

Amgen Inc. (NASDAQ:AMGN) released its quarterly earnings results on Monday, February, 1st. The medical research company reported $3.81 EPS for the quarter, topping analysts' consensus estimates of $3.39 by $0.42. The medical research company earned $6.63 billion during the quarter, compared to the consensus estimate of $6.57 billion. Amgen had a trailing twelve-month return on equity of 95.55% and a net margin of 29.42%. The company's quarterly revenue was up 7.1% on a year-over-year basis. During the same quarter in the previous year, the company earned $3.64 earnings per share.
View Amgen's earnings history
.

How has Amgen's stock price been impacted by COVID-19 (Coronavirus)?

Amgen's stock was trading at $198.65 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, AMGN shares have increased by 15.8% and is now trading at $229.99.
View which stocks have been most impacted by COVID-19
.

How often does Amgen pay dividends? What is the dividend yield for Amgen?

Amgen declared a quarterly dividend on Wednesday, December 16th. Stockholders of record on Monday, February 15th will be paid a dividend of $1.76 per share on Monday, March 8th. This represents a $7.04 dividend on an annualized basis and a yield of 3.06%. The ex-dividend date is Thursday, February 11th. This is an increase from Amgen's previous quarterly dividend of $1.60.
View Amgen's dividend history
.

Is Amgen a good dividend stock?

Amgen pays an annual dividend of $7.04 per share and currently has a dividend yield of 3.03%. Amgen does not yet have a strock track record of dividend growth. The dividend payout ratio of Amgen is 47.50%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Amgen will have a dividend payout ratio of 41.41% next year. This indicates that Amgen will be able to sustain or increase its dividend.
View Amgen's dividend history.

What guidance has Amgen issued on next quarter's earnings?

Amgen issued an update on its FY20 earnings guidance on Tuesday, February, 2nd. The company provided EPS guidance of $16.00-17.00 for the period, compared to the Thomson Reuters consensus EPS estimate of $16.16. The company issued revenue guidance of $25.8-26.6 billion, compared to the consensus revenue estimate of $25.36 billion.

What price target have analysts set for AMGN?

25 Wall Street analysts have issued twelve-month price objectives for Amgen's stock. Their forecasts range from $215.00 to $304.00. On average, they expect Amgen's stock price to reach $256.09 in the next year. This suggests a possible upside of 11.3% from the stock's current price.
View analysts' price targets for Amgen
or view top-rated stocks among Wall Street analysts.

Who are Amgen's key executives?

Amgen's management team includes the following people:
  • Mr. Robert A. Bradway, Chairman, CEO & Pres (Age 58, Pay $5.61M)
  • Mr. Jonathan P. Graham, Exec. VP, Gen. Counsel & Sec. (Age 60, Pay $2.44M)
  • Dr. David M. Reese M.D., Exec. VP of R&D (Age 58, Pay $2.54M)
  • Mr. Murdo Gordon, Exec. VP of Global Commercial Operations (Age 54, Pay $2.66M)
  • Mr. Peter H. Griffith, Exec. VP & CFO (Age 62)
  • Mr. Esteban Santos, Exec. VP of Operations (Age 53)
  • Ms. Linda H. Louie, VP of Fin. & Chief Accounting Officer
  • Mr. Mike Zahigian, Sr. VP & Chief Information Officer
  • Mr. Arvind Sood, VP of Investor Relations
  • Nancy A. Grygiel, Sr. VP of Worldwide Compliance & Bus. Ethics and Chief Compliance Officer

What is Robert A. Bradway's approval rating as Amgen's CEO?

806 employees have rated Amgen CEO Robert A. Bradway on Glassdoor.com. Robert A. Bradway has an approval rating of 91% among Amgen's employees. This puts Robert A. Bradway in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Amgen's key competitors?

What other stocks do shareholders of Amgen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amgen investors own include Johnson & Johnson (JNJ), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Pfizer (PFE), AbbVie (ABBV), The Walt Disney (DIS), AT&T (T), Alibaba Group (BABA) and The Home Depot (HD).

What is Amgen's stock symbol?

Amgen trades on the NASDAQ under the ticker symbol "AMGN."

Who are Amgen's major shareholders?

Amgen's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.21%), Primecap Management Co. CA (2.92%), FMR LLC (2.37%), Morgan Stanley (1.69%), Northern Trust Corp (1.36%) and Bank of New York Mellon Corp (1.12%). Company insiders that own Amgen stock include Cynthia M Patton, David Piacquad, David W Meline, Jonathan P Graham, R Sanders Williams and Ronald D Sugar.
View institutional ownership trends for Amgen
.

Which major investors are selling Amgen stock?

AMGN stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Nuveen Asset Management LLC, The Manufacturers Life Insurance Company , Primecap Management Co. CA, FMR LLC, Renaissance Technologies LLC, Bank of New York Mellon Corp, and Sumitomo Mitsui Trust Holdings Inc.. Company insiders that have sold Amgen company stock in the last year include Jonathan P Graham, R Sanders Williams, and Ronald D Sugar.
View insider buying and selling activity for Amgen
or view top insider-selling stocks.

Which major investors are buying Amgen stock?

AMGN stock was bought by a variety of institutional investors in the last quarter, including Morgan Stanley, Boston Partners, FIL Ltd, Beutel Goodman & Co Ltd., Canada Pension Plan Investment Board, Voloridge Investment Management LLC, Janus Henderson Group PLC, and Vontobel Holding Ltd..
View insider buying and selling activity for Amgen
or or view top insider-buying stocks.

How do I buy shares of Amgen?

Shares of AMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amgen's stock price today?

One share of AMGN stock can currently be purchased for approximately $229.99.

How much money does Amgen make?

Amgen has a market capitalization of $132.83 billion and generates $23.36 billion in revenue each year. The medical research company earns $7.84 billion in net income (profit) each year or $14.82 on an earnings per share basis.

How many employees does Amgen have?

Amgen employs 23,400 workers across the globe.

What is Amgen's official website?

The official website for Amgen is www.amgen.com.

Where are Amgen's headquarters?

Amgen is headquartered at ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320.

How can I contact Amgen?

Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The medical research company can be reached via phone at 805-447-1000 or via email at [email protected]


This page was last updated on 2/25/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.